English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -19.84%
Price change 2019 → 2020: -41.91%
Price change 2020 → 2021: 28.48%
Price change 2021 → 2022: -26.03%
Price change 2022 → 2023: -20.36%
Price change 2023 → 2024: -26.34%
Price change 2024 → 2025: -17.10%
Price change 2025 → 2026: -15.62%
Price change 2026 (year to date): -16.67%
Financial growth
Revenue CAGR (8 years): -38.08%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 22573000.00
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -2.62
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 38.36% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Innate Pharma S.A. | – | – | −2.9 % | 🔒 |
| Transgene S.A. | – | 0.02 | −20.1 % | – |
| Euroapi S.A. | – | 0.08 | −1.3 % | – |
| Cellectis S.A. | – | 1.20 | +8.9 % | – |
| Adocia S.A. | – | 5.97 | +18.8 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|